The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FGFR3 mutated (FGFR3mut+) urothelial carcinoma of bladder (UCB) or upper tract (UTUC): A comparative genomic landscape study.
 
Michael Basin
No Relationships to Disclose
 
Rebecca A Sager
No Relationships to Disclose
 
Dean C. Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN; President of Global Society of Rare GU Tumors; Société Internationale d’Urologie Journal
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Roger Li
Stock and Other Ownership Interests - Beam Therapeutics; crispr therapeutics; Editas Medicine; Guardant Health; Intellia Therapeutics; Lilly
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; CG Oncology; FerGene; Ferring; Lucence Diagnostics; Merck; Urogen pharma
Research Funding - CG Oncology; Predicine
Expert Testimony - CG Oncology
Travel, Accommodations, Expenses - CG Oncology
Other Relationship - Predicine
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Cystotech; Eisai; EnGeneIC; FerGene; Imagin Medical; Imvax; Incyte; Janssen; Medac; Merck; Nonagen Bioscience; Pfizer; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Patient-Centered Outcomes Research Institute (PCORI); Photocure; Seagen; SWOG; Taris BioMedical; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AADi; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; Dyania Health; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; Guardant Health; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology; Urogen pharma
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Liang Cheng
No Relationships to Disclose
 
Douglas I. Lin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche Pharma AG
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Alina Basnet
No Relationships to Disclose
 
Gennady Bratslavsky
Employment - AptaMatrix
Leadership - Ilgen; Taurus Diagnostics
Stock and Other Ownership Interests - Ilgen; Taurus Diagnostics
Consulting or Advisory Role - Johnson & Johnson/Janssen; Novartis
 
Joseph M Jacob
Consulting or Advisory Role - Janssen; Photocure
Speakers' Bureau - Urogen pharma